Author

Y. Hall

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Immunology· 2 Cell Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 10 Organism:mouse· 4 Organism:non-human primate· 4 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:rat· 2

Frequent Co-Authors

K. A. Ryan· 8 shared F. J. Salguero· 6 shared J. Paterson· 5 shared K. R. Bewley· 5 shared R. J. Watson· 5 shared D. Ngabo· 4 shared H. E. Humphries· 4 shared K. E. Gooch· 4 shared

Activity by Year

2017-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersMicrobiology

K. A. Ryan

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Evaluation of the cross reactivity of neutralising antibody response in vaccinated human and convalescent hamster sera against SARS-CoV-2 variants up to and including JN.1 using an authentic virus neutralisation assay

N. S. Coombes, K. R. Bewley, Y. Le Duff, N. Alami-Rahmouni, K. A. Ryan, S. Kempster, D. Ferguson, E. R. Davies, T. M. Weldon, E. S. Cross, L. Smith, C. Norris, K. R. Rogers-Broadway, K. Lewandowski, S. Treagus, , S. G. P. Funnell

This study evaluates neutralising antibody responses in vaccinated humans and convalescent hamsters against SARS-CoV-2 variants up to JN.1 using an authentic virus neutralisation assay, finding increased resistance to JN.1 in vaccinated individuals and specific neutralisation patterns in hamsters.

bioRxiv · Oct 21, 2023 · PreprintCell Biology

Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.

P. A. Wing, M. Prange-Barczynska, A. Cross, S. Crotta, C. Orbegozo Rubio, X. Cheng, J. M. Harris, X. Zhuang, R. L. Johnson, K. A. Ryan, Y. Hall, M. W. Carroll, F. Issa, P. Balfe, A. Wack, , J. A. McKeating

This study shows that activating HIF signaling reduces SARS-CoV-2 infection and respiratory symptoms in hamsters by decreasing viral RNA and epithelial damage.

bioRxiv · Mar 15, 2022Microbiology

Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant

K. A. Ryan, R. J. Watson, K. R. Bewley, C. A. Burton, O. Carnell, B. E. Cavell, A. R. Challis, N. S. Coombes, K. Emery, R. Fell, S. A. Fotheringham, K. E. Gooch, K. Gowan, A. Handley, D. J. Harris, , Y. Hall

This study shows that prior infection with a prototype SARS-CoV-2 strain protects Syrian hamsters from Omicron-induced disease.

bioRxiv · Dec 24, 2021 · PreprintMicrobiology

Rapid selection of P323L in the SARS-CoV-2 polymerase (NSP12) in humans and non-human primate models and confers a large plaque phenotype

X. Dong, H. Goldswain, R. Penrice-Randal, G. Shawli, T. Prince, M. K. Williamson, N. Randle, B. Jones, F. J. Salguero, J. Tree, Y. Hall, C. Hartley, M. Erdmann, J. Bazire, T. Jearanaiwitayakul, , J. A. Hiscox

The paper tracks the rapid emergence of the P323L mutation in SARS-CoV-2 polymerase in human and non-human primate models, showing it confers a larger plaque phenotype compared to P323.

bioRxiv · Dec 23, 2021 · PreprintMicrobiology

Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.

K. A. Ryan, K. E. Schewe, J. Crowe, S. A. Fotheringham, Y. Hall, R. Humphreys, A. C. Marriott, J. Paterson, E. Rayner, F. J. Salguero, R. J. Watson, C. J. Whittaker, M. W. Carroll, O. Dibben

This study shows that administering LAIV before or after SARS-CoV-2 infection in ferrets does not worsen disease and may reduce viral shedding.

bioRxiv · Feb 1, 2021Microbiology

Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge

K. A. Ryan, K. R. Bewley, S. A. Fotheringham, P. Brown, Y. Hall, A. C. Marriott, J. A. Tree, L. Allen, M. J. Aram, E. Brunt, K. R. Buttigieg, B. E. Cavell, D. P. Carter, R. Cobb, N. S. Coombes, , M Dennis

This study investigates the dose-dependent response of ferrets to SARS-CoV-2 infection, showing protection against re-challenge and mild clinical disease.

Nature Communications · Jan 4, 2021Peer-reviewedMicrobiology

mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

S. Rauch, K. E. Gooch, Y. Hall, F. J. Salguero, M. J. Dennis, F. V. Gleeson, D. Harris, C. Ho, H. E. Humphries, S. Longet, D. Ngabo, J. Paterson, E. L. Rayner, K. A. Ryan, S. Sharpe, , M. W. Carroll

This study shows that the mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 infection and reduces disease severity.

bioRxiv · Dec 23, 2020 · PreprintImmunology

Immunological and pathological outcomes of SARS-CoV-2 challenge after formalin-inactivated vaccine immunisation of ferrets and rhesus macaques

K. R. Bewley, K. E. R. Gooch, K. M. Thomas, S. R. Longet, N. Wiblin, L. Hunter, K. Chan, P. Brown, R. A. Russell, C. Ho, G. Slack, H. E. Humphries, L. Alden, L. Allen, M. Aram, , M. Carroll

This study evaluates vaccine-enhanced disease in ferrets and rhesus macaques after formalin-inactivated SARS-CoV-2 vaccination, finding mild transient lung pathology but no significant enhancement.

bioRxiv · Dec 21, 2020Pathology

Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19.

F. J. Salguero, A. D. White, G. S. Slack, S. A. Fotheringham, K. R. Bewley, K. E. Gooch, S. Longet, H. E. Humphries, R. J. Watson, L. Hunter, K. A. Ryan, Y. Hall, L. Sibley, C. Sarfas, L. Allen, , Tr

This study compares rhesus and cynomolgus macaques as models for mild to moderate COVID-19, showing similar viral replication, immune responses, and histopathology.

bioRxiv · Sep 17, 2020Microbiology

A novel strategy to express different antigens from one modified vaccinia Ankara vaccine vector

K. B. Lauer, E. A. McKenzie, Y. Hall, C.P.C. Gowda, P. Klapper, R. Borrow, P.J. Vallely, M. W. Carroll, T. J. Blanchard

The paper develops a modified Vaccinia Ankara vector expressing antigens from multiple pathogens and tests its immunogenicity in mice, finding that while MVA-specific antibodies were induced, no antibodies against RABV or HBV were detected.

bioRxiv · Sep 21, 2017 · PreprintImmunology